The Department of Biotechnology (DBT), in collaboration with the Biotechnology Industry Research Assistance Council (BIRAC), hosted the 14th webinar in its ongoing series on the Biofoundry and Biomanufacturing Initiative, focusing this time on “Biomanufacturing for mRNA Therapeutics.” Held on May 16, 2025, the session highlighted the critical role of mRNA therapeutics within the larger framework of the BioE3 Policy — an ambitious government effort aimed at positioning India as a global leader in bio-based innovations while promoting sustainable growth and accessible healthcare.
Dr. Alka Sharma from DBT spoke about how the BioE3 Policy envisions fostering sustainable biomanufacturing practices that support both economic development and environmental responsibility. She noted that India is witnessing a global shift toward what she called a “BioRevolution,” which holds the promise of transforming societies by advancing biotechnology. The webinar emphasized the progress Indian biotech companies and research institutions have made in developing mRNA-based vaccines and therapeutics, while also addressing persistent challenges such as product stability, delivery methods, and reliance on imported raw materials.
Dr. Varshneya Singh provided a detailed overview of the mRNA therapeutics sector, describing it as a groundbreaking frontier capable of addressing diseases ranging from cancer to genetic disorders and infectious illnesses. He shared a balanced SWOT analysis and encouraged innovators to participate in the new joint DBT-BIRAC Call for Proposals focused on Precision Biotherapeutics, aimed at accelerating research and scaling up production in this vital field.
Experts like Dr. Raghavan Varadarajan of IISc Bangalore delved into the technical aspects of mRNA-LNP vaccine technology, underscoring its revolutionary impact on medicine. His insights into vaccine design, lipid nanoparticle formulation, and innovative manufacturing techniques underscored the scientific advances driving this technology forward.
Dr. Monalisa Chatterji from Sekkei Bio Pvt. Ltd. candidly discussed the hurdles that biologics and RNA therapeutics currently face, such as limited adoption and the need for expanded manufacturing infrastructure. She stressed that significant capital investment will be crucial to unlocking the full potential of these advanced therapies and bringing them to widespread use.
The webinar concluded with an engaging question-and-answer session, where participants actively exchanged ideas, addressed regulatory concerns, and explored collaborative opportunities. This event not only reflected India’s growing commitment to cutting-edge biomanufacturing but also demonstrated a shared determination to overcome challenges and make life-saving innovations more accessible to all.
Such initiatives inspire hope and highlight the country’s resolve to balance scientific advancement with social responsibility, ensuring that the benefits of biotechnology reach every corner of the nation.
